Analys

Kancera Q4: Active in 2025, FRACTIVE in 2026 - Redeye

{newsItem.title}

Redeye Publicerad: 25 Feb 08:44

Novakand Pharma

Redeye returns following Kancera's Q4 report. We note that 2025 is shaping up to be a pivotal year, laying the foundation for the planned start of the FRACTIVE phase 2b study in 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1082927/kancera-q4-active-in-2025-fractive-in-2026?utm_source=finwire&utm_medium=RSS

Nyheter om Novakand Pharma

Läses av andra just nu

Om aktien Novakand Pharma

Senaste nytt